Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models

Activation of the PI3K/mTOR pathway has been shown to be correlated with resistance to chemotherapy in ovarian cancer. We aimed to investigate the effects of combining inhibition of mTORC1 and 2 using the mTOR kinase inhibitor vistusertib (AZD2014) with paclitaxel in in vitro and in vivo ovarian can...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong Te Fong, Anne-Christine, Thavasu, Parames, Gagrica, Sladjana, Swales, Karen E., Leach, Martin O., Cosulich, Sabina C., Chung, Yuen-Li, Banerji, Udai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768370/
https://www.ncbi.nlm.nih.gov/pubmed/29371953
http://dx.doi.org/10.18632/oncotarget.23022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768370/
https://www.ncbi.nlm.nih.gov/pubmed/29371953
http://dx.doi.org/10.18632/oncotarget.23022

Ejemplares similares